Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53

British Journal of Haematology

Volumn 138, Issue 2, 2007, Pages 253-262

  Weizer Stern, Orly ^a   Adamsky, Konstantin ^a   Margalit, Ofer ^a   Ashur Fabian, Osnat ^a   Givol, David ^b   Amariglio, Ninette ^a   Rechavi, Gideon ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Anaemia; Cancer; Hepcidin; Inflammation; Iron; p53

Indexed keywords

HEPCIDIN; INTERLEUKIN 6; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; BIOASSAY; BIOINFORMATICS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE ACTIVATION; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; IRON METABOLISM; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; STATISTICAL ANALYSIS; TEMPERATURE SENSITIVITY; TRANSCRIPTION INITIATION; TRANSIENT TRANSFECTION;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; IRON; MUTATION; RESPONSE ELEMENTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250881181     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06638.x     Document Type: Article

References (78)

1. Adamsky, K., Weizer, O., Amariglio, N., Breda, L., Harmelin, A., Rivella, S., Rachmilewitz, E. Rechavi, G. (2004) Decreased hepcidin mRNA expression in thalassemic mice. British Journal of Haematology, 124, 123 124.
2. Andrews, F.J., Morris, C.J., Lewis, E.J. Blake, D.R. (1987) Effect of nutritional iron deficiency on acute and chronic inflammation. Annals of the rheumatic diseases, 46, 859 865.
3. Ashur-Fabian, O., Adamsky, K., Trakhtenbrot, L., Cohen, Y., Raanani, P., Hardan, I., Nagler, A., Rechavi, G. Amariglio, N. (2007) Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell Cycle, 6, 589 594.
4. Atkins, M.B., Kappler, K., Mier, J.W., Isaacs, R.E. Berkman, E.M. (1995) Interleukin-6-associated anemia: determination of the underlying mechanism. Blood, 86, 1288 1291.
5. Barak, Y., Juven, T., Haffner, R. Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. The EMBO journal, 12, 461 468.
6. Barollo, M., D'Inca, R., Scarpa, M., Medici, V., Cardin, R., Fries, W., Angriman, I. Sturniolo, G.C. (2004) Effects of iron deprivation or chelation on DNA damage in experimental colitis. International Journal of Colorectal Disease, 19, 461 466.
7. Borsellino, N., Belldegrun, A. Bonavida, B. (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Research, 55, 4633 4639.
8. Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A.K. Coggi, G. (1995) p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. The American Journal of Pathology, 147, 790 798.
9. Brummelkamp, T.R., Bernards, R. Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science, 296, 550 553.
10. Chandler, D.B., Barton, J.C., Briggs, III., D.D., Butler, T.W., Kennedy, J.I., Grizzle, W.E. Fulmer, J.D. (1988) Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. The American Review of Respiratory Disease, 137, 85 89.
11. Chaston, T.B. Richardson, D.R. (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. American Journal of Hematology, 73, 200 210.
12. Chen, H.L. Carbone, D.P. (1997) p53 as a target for anti-cancer immunotherapy. Molecular Medicine Today, 3, 160 167.
13. Chen, L., Mory, Y., Zilberstein, A. Revel, M. (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proceedings of the National Academy of Sciences of the United States of America, 85, 8037 8041.
14. Choi, S., Cho, Y., Kim, H. Park, J. (2007) ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochemical and Biophysical Research Communications, 356, 312 317.
15. Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D.M., Boccadoro, M., Pileri, A. Dalla-Favera, R. (1994) Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia, 8, 758 767.
16. Courselaud, B., Pigeon, C., Inoue, Y., Inoue, J., Gonzalez, F.J., Leroyer, P., Gilot, D., Boudjema, K., Guguen-Guillouzo, C., Brissot, P., Loreal, O. Ilyin, G. (2002) C/EBPalpha Regulates Hepatic Transcription of Hepcidin, an Antimicrobial Peptide and Regulator of Iron Metabolism. Cross-talk between C/EBP pathway and iron metabolism. The Journal of Biological Chemistry, 277, 41163 41170.
17. Cummings, M.C. (1996) Increased p53 mRNA expression in liver and kidney apoptosis. Biochimica et biophysica acta, 1315, 100 104.
18. Deicher, R. Horl, W.H. (2004) Hepcidin: a molecular link between inflammation and anaemia. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 19, 521 524.
19. el-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W. Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nature Genetics, 1, 45 49.
20. Gao, J. Richardson, D.R. (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood, 98, 842 850.
21. Gehrke, S.G., Kulaksiz, H., Herrmann, T., Riedel, H.-D., Bents, K., Veltkamp, C. Stremmel, W. (2003) Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood, 102, 371 376.
22. Gerardi, G., Biasiotto, G., Santambrogio, P., Zanella, I., Ingrassia, R., Corrado, M., Cavadini, P., Derosas, M., Levi, S. Arosio, P. (2005) Recombinant human hepcidin expressed in Escherichia coli isolates as an iron containing protein. Blood Cells, Molecules & Diseases, 35, 177 181.
23. Givon, T., Slavin, S., Haran-Ghera, N., Michalevicz, R. Revel, M. (1992) Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood, 79, 2392 2398.
24. Goss, J.A., Seu, P., Gao, F.Q. Wyllie, S. (2005) Ischemia-reperfusion of rat liver modulates hepcidin in vivo expression. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 11, 800 806.
25. Gudas, J.M., Nguyen, H., Li, T., Sadzewicz, L., Robey, R., Wosikowski, K. Cowan, K.H. (1996) Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis, 17, 1417 1427.
26. Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., Kamada, N., Kobayashi, Y., Takemoto, Y., Kitani, T., Toyama, K., Ohtake, S., Yazaki, Y., Ueda, R. Hirai, H. (1996) Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood, 87, 4949 4958.
27. Hatoko, M., Tanaka, A., Kuwahara, M. Yurugi, S. (2001) Molecular response to ischemia-reperfusion of rat skin: study of expression of p53, p21WAF-1, and Bax proteins, and apoptosis. Annals of Plastic Surgery, 47, 425 430.
28. Hentze, M.W., Muckenthaler, M.U. Andrews, N.C. (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell, 117, 285 297.
29. Hilbert, D.M., Kopf, M., Mock, B.A., Kohler, G. Rudikoff, S. (1995) Interleukin 6 is essential for in vivo development of B lineage neoplasms. The Journal of Experimental Medicine, 182, 243 248.
30. Hofseth, L., Saito, S., Hussain, S., Espey, M., Miranda, K., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S., Quezado, M., Zurer, I., Rotter, V., Wink, D., Appella, E. Harris, C. (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 100, 143 148.
31. Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A.J. Ott, J. (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proceedings of the National Academy of Sciences of the United States of America, 99, 8467 8472.
32. Kaeser, M.D. Iggo, R.D. (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 99, 95 100.
33. Kemp, J.D., Cardillo, T., Stewart, B.C., Kehrberg, E., Weiner, G., Hedlund, B. Naumann, P.W. (1995) Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Research, 55, 3817 3824.
34. Komarova, E.A., Diatchenko, L., Rokhlin, O.W., Hill, J.E., Wang, Z.J., Krivokrysenko, V.I., Feinstein, E. Gudkov, A.V. (1998) Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene, 17, 1089 1096.
35. Lee, P., Peng, H., Gelbart, T., Wang, L. Beutler, E. (2005) Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proceedings of the National Academy of Sciences of the United States of America, 102, 1906 1910.
36. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323 331.
37. Levine, A.J., Momand, J. Finlay, C.A. (1991) The p53 tumour suppressor gene. Nature, 351, 453 456.
38. Loots, G.G. Ovcharenko, I. (2004) rVISTA 2·0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Research, 32, W217 221.
39. Margulies, L. Sehgal, P.B. (1993) Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. The Journal of biological chemistry, 268, 15096 15100.
40. Means, Jr., R.T. (2000) The anaemia of infection. Best Practice & Research Clinical Haematology, 13, 151 162.
41. Means, Jr., R.T. 2004) Hepcidin and anaemia. Blood Reviews, 18, 219 225.
42. Michalovitz, D., Halevy, O. Oren, M. (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62, 671 680.
43. Milward, E., Johnstone, D., Trinder, D., Ramm, G. Olynyk, J. (2007) The nexus of iron and inflammation in hepcidin regulation: SMADs, STATs, and ECSIT. Hepatology, 45, 253 256.
44. Moll, U.M., LaQuaglia, M., Benard, J. Riou, G. (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not differentiated tumors. Proceedings of the National Academy of Sciences of the United States of America, 92, 4407 4411.
45. Moretta, A. (1997) Molecular mechanisms in cell-mediated cytotoxicity. Cell, 90, 13 18.
46. Morris, C.J., Earl, J.R., Trenam, C.W. Blake, D.R. (1995) Reactive oxygen species and iron - a dangerous partnership in inflammation. The International Journal of Biochemistry & Cell Biology, 27, 109 122.
47. Mule, J.J., McIntosh, J.K., Jablons, D.M. Rosenberg, S.A. (1990) Antitumor activity of recombinant interleukin 6 in mice. Journal of Experimental Medicine, 171, 629 636.
48. Nakao, S., Kuwano, T., Ishibashi, T., Kuwano, M. Ono, M. (2003) Synergistic effect of TNF-alpha in soluble VCAM-1-induced angiogenesis through alpha 4 integrins. Journal of Immunology, 170, 5704 5711.
49. Nemeth, E., Valore, E.V., Territo, M., Schiller, G., Lichtenstein, A. Ganz, T. (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, 101, 2461 2463.
50. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T. Kaplan, J. (2004a) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306, 2090 2093.
51. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K. Ganz, T. (2004b) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113, 1271 1276.
52. Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E. Maiolo, A.T. (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood, 81, 128 135.
53. Nicolas, G., Chauvet, C., Viatte, L., Danan, J.L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A. Vaulont, S. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. Journal of clinical investigation, 110, 1037 1044.
54. Niedobitek, G., Agathanggelou, A., Barber, P., Smallman, L.A., Jones, E.L. Young, L.S. (1993) P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. The Journal of Pathology, 170, 457 461.
55. Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J.A. Tanaka, N. (1999) Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for Bystander effect. Clinical Cancer Research, 5, 1015 1023.
56. Ostermeyer, Anne, G., Runko, E., Winkfield, B., Ahn, B. Moll Ute, M. (1996) Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proceedings of the National Academy of Sciences of the United States of America, 93, 15190 15194.
57. Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C. Trautwein, C. (2007) STAT3 is required for IL-6-gp130-dependent activation of Hepcidin in vivo. Gastroenterology, 132, 294 300.
58. Preudhomme, C., Facon, T., Zandecki, M., Vanrumbeke, M., Lai, J., Nataf, E., Loucheux-Lefebvre, M.H., Kerckaert, J.P. Fenaux, P. (1992) Rare occurrence of P53 gene mutations in multiple myeloma. British journal of haematology, 81, 440 443.
59. Rayanade, R.J., Ndubuisi, M.I., Etlinger, J.D. Sehgal, P.B. (1998) Regulation of IL-6 signaling by p53: STAT3- and STAT5-masking in p53-Val135-containing human hepatoma Hep3B cell lines. Journal of Immunology, 161, 325 334.
60. Richardson, D.R. (2002) Iron chelators as therapeutic agents for the treatment of cancer. Critical Reviews in Oncology/Hematology, 42, 267 281.
61. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Burg, Sjoerd Van, D., Nijman Hans, W., Melief Cornelis, J.M. Claesson Mogens, H. (1996) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proceedings of the National Academy of Sciences of the United States of America, 93, 14704 14707.
62. Santhanam, U., Ray, A. Sehgal, P.B. (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proceedings of the National Academy of Sciences of the United States of America, 88, 7605 7609.
63. Shaulsky, G., Goldfinger, N., Peled, A. Rotter, V. (1991a) Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research, 2, 661 667.
64. Shaulsky, G., Goldfinger, N., Tosky, M., Levine, A.J. Rotter, V. (1991b) Nuclear localization is essential for the activity of p53 protein. Oncogene, 6, 2055 2065.
65. Siemann, D.W., Chaplin, D.J. Horsman, M.R. (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer, 100, 2491 2499.
66. Simonart, T., Degraef, C., Andrei, G., Mosselmans, R., Hermans, P., Van Vooren, J.P., Noel, J.C., Boelaert, J.R., Snoeck, R. Heenen, M. (2000) Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. The Journal of Investigative Dermatology, 115, 893 900.
67. Srisuma, S., Biswal, S.S., Mitzner, W.A., Gallagher, S.J., Mai, K.H. Wagner, E.M. (2003) Identification of genes promoting angiogenesis in mouse lung by transcriptional profiling. American Journal of Respiratory Cell and Molecular Biology, 29, 172 179.
68. Tak, P.P., Zvaifler, N.J., Green, D.R. Firestein, G.S. (2000) Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunology Today, 21, 78 82.
69. Theobald, M., Biggs, J., Dittmer, D., Levine, A.J. Sherman, L.A. (1995) Targeting p53 as a General Tumor Antigen. Proceedings of the National Academy of Sciences of the United States of America, 92, 11993 11997.
70. Verga Falzacappa, M.V., Vujic Spasic, M., Kessler, R., Stolte, J., Hentze, M.W. Muckenthaler, M.U. (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood, 109, 353 358.
71. Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A.M., Anasagasti, M.J., Martin, J., Carrascal, T., Walsh, P., Reznikov, L.L., Kim, S.H., Novick, D., Rubinstein, M. Dinarello, C.A. (2000) IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 734 739.
72. Vousden, K.H. Lu, X. (2002) Live or let die: the cell's response to p53. Nature Reviews Cancer, 2, 594 604.
73. Weinberg, E.D. (1999a) Iron loading and disease surveillance. Emerging Infectious Diseases, 5, 346 352.
74. Weinberg, E.D. (1999b) Development of clinical methods of iron deprivation for suppression of neoplastic and infectious diseases. Cancer Investigation, 17, 507 513.
75. Wrighting, D.M. Andrews, N.C. (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood, 108, 3204 3209.
76. Yang, D.C., Jiang, X.P., Elliott, R.L. Head, J.F. (2001) Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Research, 21, 1777 1787.
77. Yasuga, Y., Hirosawa, S., Yamamoto, K., Tomiyama, J., Nagata, J. Aokia, N. (1995) N-ras and p53 gene mutations are very rare events in multiple myeloma. International Journal of Hematology, 62, 91 97.
78. Zhou, X., Wang, X.W., Xu, L., Hagiwara, K., Nagashima, M., Wolkowicz, R., Zurer, I., Rotter, V. Harris, C.C. (1999) COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research, 59, 843 848.